Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen RAVICTI (glycerol phenylbutyrate by Year
RAVICTI (glycerol phenylbutyrate — Urea Cycle Disorders) — U.S. sales ($M) ($M)
Amgen RAVICTI (glycerol phenylbutyrate: $337M in FY2025, down 14.9% from a year earlier.
Where the FY2025 figure comes from
“|| RAVICTI — U.S. (1) | 337 | (15) | % | 396 | * | 86”
Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Other Product Sales by Geographic Region Footnote.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | RAVICTI (glycerol phenylbutyrate — Urea Cycle Disorders) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 337 | -14.9% | Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 396 | +360.5% | Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 86 | – | Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗ |
Breakdown
What makes up RAVICTI (glycerol phenylbutyrate
Cite this data
StockData. (2026). Amgen RAVICTI (glycerol phenylbutyrate ($M), annual FY2023–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-ravicti-us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.